Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New test may reveal hidden cancer after liver ablation

NCT ID NCT01494324

Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at tissue from liver tumors that were destroyed using heat or cold (ablation). The goal is to see if a special test on that tissue can tell whether the treatment fully killed the cancer, which standard CT scans cannot always do. About 150 people with liver cancer that spread from another part of the body are taking part. The results may help doctors better predict and monitor treatment success in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

150 people

The number who actually took part.

Started

Oct 2009

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with diagnosed with secondary hepatic malignancy; * Patients with confined liver disease or stable limited extrahepatic disease; * Lesions of 5cm or less in maximum diameter; * Patients who are not surgical candidates or refuse to undergo surgery and choose any percutaneous ablation as an alternative treatment option. * INR\<1.5 \*for patients on Coumadin general clinical guidelines for IR ablation will be followed. * Platelet count \> or = to 50,000 Exclusion Criteria: * Patients \< 18 * Less than 5 mm distance of the tumor margin from a major vessel \>7mm in diameter)\*\* * Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from\*\* * the ablation injury with technical modifications such as hydro or air dissection. * INR \> 1.5 that cannot be corrected with fresh frozen Plasma\* * Platelet count of \<50,000 that cannot be corrected with transfusion. * Patient with more than 3 tumors treated with any percutaneous ablation * Patients with more than 5 sites of extrahepatic disease (including nodes and pulmonary nodules) * for patients on Coumadin general clinical guidelines for IR ablation will be followed \*\*This will not be considered an exclusion criteria when IRE or Microwave is used. * This will not be considered exclusion when IRE is used

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver cancer Liver Neoplasms secondary malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cancer

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.